title: Preclinical safety evaluation of the aqueous acetone extract of Chinese herbal formula Modified Huo Luo Xiao Ling Dan.
abstract: OBJECTIVE
  To investigate the safety of oral administration of Modified Huo Luo Xiao Ling Dan (HLXLD), a compound traditional Chinese herbal medicine.
  
  
  METHODS
  The toxicological information of HLXLD and its individual constituent herbs was searched in cintcm or TCMlars (www.cintcm.com), PubMed (MEDLINE), Chinese Herbal Medicine (1999) and WHO Monographs on Selected Medicinal Plants (Vol. I- III). Single-dose acute toxicity was assessed by using the highest possible dosage. Motor function test was used to determine whether the herbal formula might cause motor impairment. Nine-day HLXLD repeat-dose sub-chronic toxicity/adverse effects, and 42-day chronic toxicity/adverse effects in rats were also assessed.
  
  
  RESULTS
  The literature searches showed that HLXLD and its eleven ingredient herbs had no side/adverse effects listed in the traditional Chinese medicine literature. Under the dosages proposed in the formula, the HLXLD formula had no side/adverse effects according to MEDLINE, Chinese Herbal Medicine and WHO Monographs on Selected Medicinal Plants. The studies in rats showed: (1) in single-dose acute toxicity assessment, the maximal feasible single oral dose, 9.20 g/kg HLXLD, showed no significant effect on clinical signs, or body weight and mortality over a 14-day period in rats; (2) during motor function test, nine-day repeat-dose of daily HLXLD treatment at 4.60 g/kg did not cause motor impairment; (3) in nine-day HLXLD repeat-dose sub-chronic toxicity/adverse effects assessment, there were no noticeable abnormal behavioral changes or obvious adverse reactions and signs in complete Freund's adjuvant inflamed rats (highest observed dosage: 4.60 g/kg), and no noticeable adverse effects were observed during, or 14 days after nine-day treatment at 4.60 g/kg in non-inflamed rats; (4) during 42-day chronic toxicity/adverse effects assessments, no noticeable abnormal behavioral changes, no obvious adverse reactions and signs were observed in normal rats administered with HLXLD at a dose of 2.30 g/kg and the values of serum biochemistry and histopathology were in normal range.
  
  
  CONCLUSIONS
  Both existing information and animal data support that Modified HLXLD is a safe herbal product for clinical application.
authors.affiliation: Center for Integrative Medicine, University of Maryland, Baltimore, MD 21201, USA. ArthurFan@ChineseMedicineDoctor.US
authors.forename: Arthur Yin
authors.initials: AY
authors.lastname: Fan
authors.forename: Lixing
authors.initials: L
authors.lastname: Lao
authors.forename: Rui-xin
authors.initials: RX
authors.lastname: Zhang
authors.forename: An-nan
authors.initials: AN
authors.lastname: Zhou
authors.forename: Brian M
authors.initials: BM
authors.lastname: Berman
mesh_terms: D000818:Animals; D004353:Drug Evaluation, Preclinical; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage / Q000009:adverse effects*; D010936:Plant Extracts / Q000008:administration & dosage / Q000009:adverse effects*; D051381:Rats; D017207:Rats, Sprague-Dawley; D036401:Toxicity Tests, Chronic
chemical_list: D004365:Drugs, Chinese Herbal; D010936:Plant Extracts; C547651:huo luo xiao ling dan
references.citation: J Ethnopharmacol. 2005 Oct 3;101(1-3):104-9
references.pmid: 15970410
references.citation: Am J Chin Med. 2006;34(5):833-44
references.pmid: 17080548
references.citation: Zhongguo Zhong Yao Za Zhi. 2001 Jun;26(6):369-72
references.pmid: 12528501
references.citation: Encephale. 2004 Sep-Oct;30(5):417-24
references.pmid: 15627046
references.citation: Photodermatol Photoimmunol Photomed. 1991 Apr;8(2):84-5
references.pmid: 1756118
references.citation: Pain. 1983 Jun;16(2):109-110
references.pmid: 6877845
references.citation: J Clin Psychiatry. 2005 Feb;66(2):260-4
references.pmid: 15705014
references.citation: J Altern Complement Med. 2005 Apr;11(2):323-31
references.pmid: 15865500
references.citation: Rheumatology (Oxford). 2003 May;42(5):665-72
references.pmid: 12709543
references.citation: J Pain. 2001 Apr;2(2):111-7
references.pmid: 14622832
references.citation: J Hum Hypertens. 2001 Aug;15(8):549-52
references.pmid: 11494093
references.citation: Am J Health Syst Pharm. 2000 Jul 1;57(13):1221-7; quiz 1228-30
references.pmid: 10902065
references.citation: J Altern Complement Med. 1999 Oct;5(5):429-36
references.pmid: 10537242
references.citation: J Ethnopharmacol. 2009 Jan 30;121(3):366-71
references.pmid: 19100323
references.citation: Zhongguo Zhong Xi Yi Jie He Za Zhi. 1994 Oct;14(10):583-5
references.pmid: 7719087
references.citation: Adv Data. 2004 May 27;(343):1-19
references.pmid: 15188733